Semaglutide: The Complete Guide
The GLP-1 peptide that reshaped weight loss — known as Ozempic and Wegovy. Here's how it works, what the clinical trials actually showed, and what to know before considering it.
This guide summarizes published clinical research on semaglutide. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
Few compounds have changed a field the way semaglutide changed weight management. When its landmark trial data was published, it showed something previously thought possible only through surgery: substantial, sustained weight loss from a weekly injection. It became a household name almost overnight — under the brands Ozempic and Wegovy — and reshaped how medicine approaches obesity.
This guide explains what semaglutide is, how it produces its effects, exactly what the clinical trials demonstrated, how it's dosed, and the practical realities of side effects and considerations — all grounded in the published research.
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist — a peptide that mimics a natural gut hormone called glucagon-like peptide-1 (GLP-1). Your body releases GLP-1 after you eat; it helps regulate blood sugar and signals fullness. The catch is that natural GLP-1 breaks down within minutes. Semaglutide is engineered to resist that breakdown, so a single injection keeps working for about a week — which is why it's dosed just once weekly.
It was originally developed for type 2 diabetes (GLP-1 helps control blood sugar), but researchers noticed a consistent, striking side effect: significant weight loss. That observation led to dedicated obesity trials and, ultimately, to semaglutide becoming the defining weight-loss medication of its era.
The Names Explained (Ozempic vs Wegovy vs Rybelsus)
One source of confusion is that the same molecule — semaglutide — is sold under different brand names for different uses. Here's the plain breakdown:
| Brand | Primary Use | Form |
|---|---|---|
| Ozempic | Type 2 diabetes (used off-label for weight) | Weekly injection, up to 2 mg |
| Wegovy | Weight management (obesity) | Weekly injection, up to 2.4 mg |
| Rybelsus | Type 2 diabetes | Daily oral tablet |
They're all semaglutide — the differences are the approved use, the dose, and the form. The weight-loss trial results most people cite come from the higher 2.4 mg dose (Wegovy). As of 2026, an oral tablet form of semaglutide for weight loss has also been approved, expanding the options beyond injection.
How It Works
Semaglutide produces weight loss through several complementary actions — it's not a stimulant or a "fat burner," but a hormone signal that changes how much you want to eat.
Reduces Appetite
It acts on appetite centers in the brain, reducing hunger and cravings. Most people simply feel satisfied with less food — the central mechanism behind the weight loss.
Slows Gastric Emptying
It slows how quickly the stomach empties, so you feel full longer after eating. This is also the source of most of its digestive side effects.
Improves Blood Sugar Control
It prompts insulin release when blood sugar is high and reduces excess glucose output — the original diabetes mechanism.
Quiets "Food Noise"
Many users describe a reduction in constant intrusive thoughts about food, making it easier to eat less without white-knuckle willpower.
The key insight
Semaglutide works largely by reducing appetite — it makes eating less feel natural rather than forced. That "food noise" reduction is what many people find most striking: the constant background pull toward food quiets down. This is why it succeeds where willpower-based dieting often fails — it addresses the biological drive to eat, not just the behavior.
What the Trials Showed
Semaglutide's reputation rests on an unusually strong body of clinical trial evidence — the STEP program (Semaglutide Treatment Effect in People with obesity).
The Landmark Result
In the pivotal STEP 1 trial (published in the New England Journal of Medicine in 2021), 1,961 adults with obesity or overweight — without diabetes — received either weekly semaglutide 2.4 mg or placebo, alongside lifestyle support. After 68 weeks, the semaglutide group lost an average of about 14.9% of their body weight, compared to roughly 2.4% with placebo. For a non-surgical treatment, reaching close to 15% average weight loss was a genuine turning point — a level previously thought achievable only through bariatric surgery.
It Lasts
The STEP 5 trial extended the picture to two years, showing that the weight loss was sustained with continued treatment — this isn't just a short-term effect that quickly rebounds while you stay on it. Across the STEP program, results were consistent, and beyond weight, semaglutide has also shown cardiovascular benefits in separate research.
An honest note on stopping
One important, well-documented finding: much of the weight tends to return after stopping semaglutide, because the appetite-regulating effect ends when the medication does. This has reframed how the compound is understood — as an ongoing tool for managing a chronic condition (like blood pressure medication) rather than a short course that permanently "fixes" weight. It's worth going in with that realistic understanding.
Dosing & Titration
Semaglutide dosing follows one firm principle: start low and increase slowly. This gradual titration is the single most important factor in tolerating it well. The ranges below reflect the standard approach used in trials and labeling. They are general informational references, not medical recommendations.
| Phase | Typical Weekly Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Adaptation — not expected to drive weight loss yet |
| Weeks 5–8 | 0.5 mg | Continued adaptation |
| Weeks 9–12 | 1.0 mg | Building toward an effective dose |
| Weeks 13–16 | 1.7 mg | Approaching target |
| Week 17+ | 2.4 mg (target) | The full weight-management dose from the trials |
Why you can't rush this
The 0.25 mg starting dose is about tolerability, not effectiveness — you shouldn't expect much weight loss at the lowest doses, and that's by design. Skipping steps or escalating too fast is the single most common cause of severe, intolerable nausea and of people quitting altogether. Your digestive system needs time to adapt to slowed gastric emptying. Patience through the titration is what makes the difference between tolerating it well and having a miserable experience. Some people also stay at a lower dose that works for them rather than always pushing to the maximum.
Semaglutide comes as a solution or is reconstituted from powder with bacteriostatic water, then injected subcutaneously once weekly. See our reconstitution and dosing basics guides, and our tropical storage guide for keeping it stable in the heat.
Side Effects & Managing Them
Semaglutide's side effects are predictable and mostly digestive — a direct consequence of how it slows the gut. The good news is they're usually most intense early on and fade as your body adjusts, and there's a lot you can do to minimize them.
Common (usually transient)
- Nausea — the most common, especially early and after dose increases
- Constipation or diarrhea
- Reduced appetite (the intended effect, but worth eating enough nutrition)
- Bloating, burping, or reflux
- Fatigue, particularly early on
Practical ways to reduce them
- Eat smaller portions — slowed emptying means large meals feel worse
- Favor bland, lower-fat foods when nausea is present; go easy on greasy and very rich meals
- Stay hydrated, which also helps with constipation
- Don't rush the dose titration — this is the biggest lever
- Eat enough protein and stay active (see the muscle note below)
When to seek medical attention
Contact a healthcare professional if you can't keep food or water down, or if you experience severe or persistent abdominal pain (especially pain radiating to the back, which can signal pancreatitis — a rare but serious concern). Rapid weight loss can also raise the risk of gallstones. These are uncommon, but they're the situations where medical input matters. See our when to consult a doctor guide.
The Muscle-Loss Consideration
One increasingly discussed aspect of GLP-1 weight loss deserves honest attention: some of the weight lost is lean muscle, not just fat. Research suggests that roughly 25–40% of the weight lost on GLP-1 medications can come from lean mass. This isn't unique to semaglutide — significant weight loss from any cause involves some muscle loss — but it's worth actively countering.
How to protect your muscle
Two countermeasures matter most: eat enough protein (this becomes harder when your appetite is suppressed, so it needs to be deliberate) and do resistance training (lifting weights or bodyweight work signals your body to preserve muscle). Losing weight while keeping muscle gives a better body composition and metabolic outcome than just watching the scale drop. This is important enough that we cover it — and how growth-hormone peptides sometimes factor in — as part of a broader metabolic strategy.
How It Compares
Semaglutide is one of three major players in this space, and where it fits is worth understanding.
| Compound | Mechanism | Trial Weight Loss (approx.) |
|---|---|---|
| Semaglutide | GLP-1 (single) | ~15% (68 weeks) |
| Tirzepatide | GLP-1 + GIP (dual) | ~20–22% (higher-dose trials) |
| Retatrutide | GLP-1 + GIP + glucagon (triple) | ~24%+ (trials ongoing) |
In short: semaglutide is the established, most-studied option with the longest track record; tirzepatide (a dual agonist) has shown somewhat greater average weight loss; and retatrutide (a triple agonist) is the newest, with the highest figures in trials still underway. Semaglutide's strength is its unmatched depth of evidence and real-world experience. For a full side-by-side, see our Retatrutide vs Semaglutide vs Tirzepatide comparison, and our Retatrutide complete guide.
Safety & Who Should Avoid It
Semaglutide has been used by millions of people and studied extensively, with a well-characterized safety profile. Still, it's not for everyone.
Who should not use semaglutide
Semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer) or a condition called Multiple Endocrine Neoplasia type 2 (MEN 2), based on findings in animal studies. It should be avoided in pregnancy and breastfeeding, by people with a history of pancreatitis, and used with caution alongside diabetes medications (see below). Anyone with a history of gallbladder disease, severe gastrointestinal conditions, or an eating disorder should consult a doctor first.
The Key Drug Interaction
The most important interaction is with other blood-sugar-lowering medications. Combining semaglutide with insulin or sulfonylureas can push blood sugar too low (hypoglycemia), so those medications often need adjustment by a doctor. Semaglutide's slowing of gastric emptying can also affect the absorption of some oral medications. Our drug interactions guide covers this in detail — this is a genuinely important one to get right if you take other medications.
Common Questions
How much weight can you lose on semaglutide?
In the pivotal STEP 1 trial, people without diabetes lost an average of about 14.9% of their body weight over 68 weeks at the 2.4 mg weekly dose, compared to about 2.4% on placebo. Individual results vary — some lose more, some less — and results depend on dose, consistency, and lifestyle. It's worth noting the trial figure is an average at the full dose reached through proper titration, alongside lifestyle support.
What's the difference between Ozempic and Wegovy?
They're the same molecule — semaglutide — sold under different brand names. Ozempic is branded for type 2 diabetes (up to 2 mg weekly) and is often used off-label for weight, while Wegovy is branded for weight management at a higher 2.4 mg dose. The weight-loss trial results most people cite come from the Wegovy (2.4 mg) dose. Rybelsus is a third brand — a daily oral tablet form used for diabetes.
Why do I have to start at such a low dose?
The 0.25 mg starting dose is entirely about tolerability, not effectiveness — you're not expected to lose much weight at it. Your digestive system needs time to adapt to slowed gastric emptying, and starting too high or escalating too fast is the number-one cause of severe nausea and of people quitting. The slow titration (increasing roughly every 4 weeks) is what lets most people tolerate it well. Patience here genuinely pays off.
Will I regain the weight if I stop?
Research shows much of the weight tends to return after stopping, because semaglutide works by regulating appetite — and that effect ends when the medication does. This is why it's increasingly understood as an ongoing tool for managing a chronic condition (like blood pressure medication) rather than a short-term fix. Building sustainable habits during treatment, and discussing any transition with a doctor, helps — but it's important to go in with realistic expectations.
How do I handle the nausea?
Nausea is the most common side effect, usually worst early and after dose increases, and it typically fades as you adjust. The biggest lever is not rushing the dose titration. Beyond that: eat smaller portions, favor bland lower-fat foods when queasy, avoid greasy or very rich meals, and stay hydrated. If you genuinely can't keep food or water down, that's a reason to contact a healthcare professional rather than push through.
Is semaglutide or tirzepatide better?
Tirzepatide has shown somewhat greater average weight loss in trials (~20–22% vs ~15%), likely because it acts on two receptors (GLP-1 and GIP) rather than one. But semaglutide has the longer track record and deeper body of evidence and real-world experience. "Better" depends on your priorities — proven track record versus higher average results, plus individual tolerance. Our comparison guide covers the trade-offs in detail.
Should I worry about losing muscle?
It's worth being aware of: research suggests roughly 25–40% of weight lost on GLP-1 medications can be lean mass, though this happens with significant weight loss from any cause. The countermeasures are straightforward and effective — eat enough protein (which takes deliberate effort when your appetite is down) and do resistance training. Doing both helps ensure more of what you lose is fat, giving a better body-composition result.
Is semaglutide legal in Costa Rica?
Semaglutide is sold as a research compound in Costa Rica, the same framework used in most countries with active peptide markets, for laboratory and research purposes. Buying locally avoids the heat exposure that international shipping puts delicate peptides through. See our FAQ page for more.
Questions about semaglutide?
Whether you want to understand how semaglutide works, how it compares to other options, or how to approach the titration, reach out. We answer every message personally — no pressure, no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. While semaglutide is an FDA-approved medication under brand names like Ozempic and Wegovy when prescribed by a licensed clinician, research-grade semaglutide is sold as a research compound intended for laboratory and scientific study and is not a substitute for prescribed, medically supervised treatment. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and should be avoided in pregnancy and breastfeeding. Always consult a qualified healthcare professional before beginning any peptide protocol, especially if you take diabetes medications, have a medical condition, or take other medications. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- New England Journal of Medicine (Wilding et al., 2021): "Once-Weekly Semaglutide in Adults with Overweight or Obesity" — the STEP 1 trial.
- Nature Medicine (Garvey et al., 2022): "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial."
- FDA Prescribing Information: Wegovy and Ozempic (semaglutide) labeling — dosing, contraindications, and warnings.
- New England Journal of Medicine: SUSTAIN and SELECT program — glycemic and cardiovascular outcomes.
- NCBI/PMC: GLP-1 receptor agonists — mechanism, lean-mass considerations, and gastrointestinal tolerability.
- StatPearls (NCBI): "Glucagon-Like Peptide-1 Receptor Agonists" — drug interactions and hypoglycemia risk.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
